SCHEMBL848673

SCHEMBL848673

Cc1cc(-n2ccc(=O)[nH]c2=O)cc(C)c1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 4/20 0.53
DDB1 Q16531 1/20 0.53
ALDH1A1 P00352 4/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HCAR1 Q9BXC0 5/20 0.38
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PKM P14618 1/20 0.34
CSNK2A2 P19784 1/20 0.33
CSNK2B P67870 1/20 0.33
CSNK2A1 P68400 1/20 0.33
ATM Q13315 1/20 0.33
TYMP P19971 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25565822 0.82 CRBN (0.56) CRBNDDB1ALDH1A1LMNAGAA
SCHEMBL23296161 0.81 CRBN (0.51) CRBNDDB1ALDH1A1LMNAGAA
SCHEMBL11478341 0.80 CRBN (0.58) CRBNDDB1ALDH1A1HCAR1MAPT
SCHEMBL26683671 0.75 CRBN (0.45) CRBNDDB1ALDH1A1LMNAGAA
SCHEMBL3340320 0.75 CRBN (0.51) CRBNDDB1ALDH1A1LMNAGAA
SCHEMBL12769062 0.74 CRBN (0.44) CRBNDDB1ALDH1A1HCAR1NPC1
SCHEMBL21995599 0.74 CRBN (0.66) CRBNDDB1ALDH1A1POLBNPSR1
SCHEMBL11479782 0.74 CRBN (0.60) CRBNDDB1ALDH1A1LMNAHCAR1
SCHEMBL5325743 0.74 CRBN (0.66) CRBNDDB1ALDH1A1HCAR1MAPT
SCHEMBL14685529 0.74 CRBN (0.65) CRBNDDB1ALDH1A1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 US disclosed
US-20160016956-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-21 US disclosed
EP-2433940-B9 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2015-10-28 EP disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 US disclosed
EP-2433940-B1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2014-09-24 EP disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 CRBN 1932/4885DDB1 4325/4885ALDH1A1 836/4885
US-20160016956-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 CRBN 1932/4885DDB1 4325/4885ALDH1A1 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.